A comparative effectiveness program launched by Geisinger Health has reportedly slowed the rapid increase in biologic spending, according to an HFMA report. According to the report, Geisinger Health Plan's spending on biologics accounted for about 35.9 percent of its total drug spending in 2018, […]
ICER Set to Review Canakinumab for Atherosclerosis
The Institute for Clinical and Economic Review (ICER) on Monday announced its plans to analyze the comparative clinical effectiveness and value of Novartis' canakinumab to reduce cardiovascular risk in patients diagnosed with atherosclerosis. ICER in a press release said the report will be reviewed […]
IBD Therapy Trial Receives $2.4 Million Grant
A comparative study of new biologic and small-molecule treatments for inflammatory bowel disease is slated to receive $2.4 million in grant funding from the Patient-Centered Outcomes Research Institute and the Crohn's and Colitis Foundation (CCF). According to a Healio report, the study will […]
ICER Releases Report on Plaque Psoriasis Treatments
The Institute for Clinical and Economic Review (ICER) on Friday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for moderate-to-severe plaque psoriasis. The review will be open to public comment until May 25. Findings contained in this […]
ICER Set to Review Biologic Treatments for Asthma
The Institute for Clinical and Economic Review (ICER) on Tuesday announced plans to develop a review assessing the comparative clinical effectiveness and value of biologic therapies for moderate-to-severe asthma. The report is set to be reviewed during a November public meeting of the Midwest […]
Articles in Journal Highlight Efforts to Better CER
Three articles in the Journal of Comparative Effectiveness Research focus on the work and recommendations of a CER-centric conference convened last year by the PhRMA Foundation and the Academy of Managed Care Pharmacy. The articles push for steps that aim to ensure future decisions regarding […]
ICER Reports to Assess Amyloidosis, Prostate Cancer Treatments
The Institute for Clinical and Economic Review (ICER) says upcoming reports will focus on the comparative clinical effectiveness and value of high-risk prostate cancer and hereditary amyloidosis treatments. According to a press release, the reports will be reviewed during the September meeting of […]
What Role do Payers Play in the Opioid Crisis?
Listen to Judy Zerzan from the Colorado Department of Health Care Policy & Financing talk on the role of payers in the opioid crisis in this short clip. View here. (Source: PCORI, 1/23/18) […]
ICER Releases Report on Emicizumab for Hemophilia A
The Institute for Clinical and Economic Review recently released a Draft Evidence Report assessing the comparative clinical effectiveness and value of emicizumab. The Draft Evidence Report and Draft Voting Questions are now open to public comment until February 23rd at 5 PM ET. Find out more here. […]
German Drug Assessment Watchdog Pushes Direct Comparison of Cancer Immunotherapies
IQWiG, and independent drug assessment body in Germany, is pushing for direct comparison data in a new class of cancer immunotherapies. The move comes as the watchdog speaks out against what it says is a lack of data in the class of immunotherapies, suggesting physicians could be either overwhelmed […]
ICER Report Recommends Voretigene Neparvovec Price Discount
The Institute for Clinical and Economic Review (ICER) on Friday released its revised Evidence Report assessing the comparative clinical effectiveness and value of voretigene neparvovec (Luxturna, Spark Therapeutics) for treatment of vision loss associated with biallelic RPE65-mediated retinal […]
BSBSA Chief Medical Officer: CER ‘Very Critical When You Have Options’
Blue Cross Blue Shield Association Chief Medical Office Trent Haywood discussed comparative effectiveness research and how it could facilitate personalized decisions on health care. "Comparative effectiveness research, to me, is very critical when you have options, and when you're considering the […]
ICER to Assess Elagolix for Management of Endometriosis
The Institute for Clinical and Economic Review (ICER) will assess the comparative clinical effectiveness and value of elagolix (AbbVie) for management of endometriosis with associated pain. The FDA’s decision on whether to approve elagolix is expected during the second quarter of 2018. An Open […]
ICER to Assess Erenumab for Migraines, Guselkumab and Tildrakizumab
The Institute for Clinical and Economic Review (ICER) will assess the comparative clinical effectiveness and value of erenumab (Amgen/Novartis) for prevention of migraine headaches. The FDA’s decision on whether to approve erenumab is expected in May of 2018. In addition, ICER will conduct an […]
ICER Releases Report on Tardive Dyskinesia Treatments
The Institute for Clinical and Economic Review(ICER) released a Draft Evidence Report assessing the comparative clinical effectiveness and value of therapies to treat tardive dyskinesia, a movement disorder often associated with long-term use of antipsychotic medications. The report, along with […]
ICER Publishes Report on Mind-Body Therapies
The Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness of several cognitive and mind-body therapies for treatment of chronic low back and neck pain, including acupuncture, cognitive behavioral therapy (CBT), […]
Biopharma Companies Pledge $500,000 to PAI’s hēRo3
PAI announced three biopharma companies have pooled $500,000 for the final development phase of its hēRo3, a new open-source platform for running cost-effectiveness models. The platform is slated to undergo extensive testing in October by PAI's development partners and HTA agencies. After testing, […]
Health Affairs Blog: RWE a Welcome Addition to Randomized Controlled Trials
A Health Affairs Blog post says real-world evidence (RWE) complements randomized controlled trials, which sometimes have limitations in comparative effectiveness research. As the health care industry begins its slow shift toward a more value-based payment system, accurate and reliable data is […]
Eyeforpharma Spotlights Data, Pragmatic Trials in Interview
The undeniable power of data is becoming more apparent by the day, and is poised to revamp the current health care landscape through real-world data. Eyeforpharma sat down with Janssen Real-World Evidence Team Leader Jack Sheehan and Riccardo Perfetti, Sanofi senior medical officer and vice […]
Outcomes-Based Pricing for PCSK9 Inhibitors
Via the American Journal of Managed Care: "In 2015, the FDA approved the PCSK9 inhibitors evolocumab and alirocumab for lowering low-density lipoprotein cholesterol (LDL-C). The approval of these agents was based on clinical trials that found PCSK9 inhibitors reduced LDL-C levels by around […]
FDA Urges Stronger Clinical Research
U.S. Food and Drug Administration (FDA) officials and health care industry leaders say it's necessary to reassess the standards of evidence and dependability of information during regulatory discussions, Applied Clinical Trials reports. FDA Commissioner Scott Gottlieb at an Impact of Real World […]
ICER Posts Draft Scoping Document for Emicizumab Review
Via the Institute for Clinical and Economic Review: The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document outlining its planned review of the comparative clinical effectiveness and value of emicizumab for prevention of bleeding in patients with hemophilia A who […]
ICER: Inadequate Evidence to Compare PARP Inhibitors Across Ovarian Cancer Indications
The Institute for Clinical and Economic Review on Wednesday published an evidence report on the comparative clinical effectiveness and value of three inhibitors used in ovarian cancer treatments. "PARP inhibitors have the potential to improve upon existing treatment paradigms for women who […]
VIDEO: NPC Research VP Discusses Decision-Making by Payers
The National Pharmaceutical Council's Vice President of Comparative Effectiveness Research Jennifer Graff says payers use a wide swath of information to make coverage and reimbursement decisions. Graff said in an interview with the American Journal of Managed Care that the best evidence could […]
VIDEO: PCORI Executive Director talks CER
In a video posted Thursday by the Patient-Centered Outcomes Research Institute, Joe Selby, the institute's executive director, discussed some challenges facing efficient comparative effectiveness research. "There are a lot of methodological questions about how one does comparative effectiveness […]
Correlating Surrogate Endpoints with RWE in Oncology
Via the American Journal of Managed Care: "A new study has analyzed data from randomized controlled trials (RCTs) in oncology that used surrogate endpoints and measured their relation with treatment effectiveness and patient survival in the real world. A significant concern with using surrogate […]
Goodman: Value Frameworks Always Evolving
Clifford Goodman, senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group, said in an interview value frameworks are continually evolving and adapting in the health care marketplace. "Value frameworks also recognize that value is the in the eye of […]
ICER: Osteoporosis Anabolic Agents Priced Too High
In a Final Evidence Report on the comparative clinical effectiveness and value of teriparatide and abaloparatide, the Institute of Clinical and Economic Review (ICER) found the price of both agents was "too high." Teriparatide and abaloparatide are anabolic agents used in osteoporosis […]
Same Condition, Different Costs: NPC to Address Contentious Question
The National Pharmaceutical Council (NPC) will bring to focus a contentious issue in the health care industry: Why do some patients with the same condition sometimes have different out-of-pocket costs than others for their medicines? In a free, online webinar titled "Same Condition, Different […]
ICER Announces Draft Scoping Document on Retinal Disease Therapy
The Institute for Clinical and Economic Review (ICER) posted a Draft Scoping Document which will be involved in a report on voretigene neparvovec. According to a press release from ICER, voretigene neparvovec is a therapy used to help people suffering from "vision loss associated with biallelic […]
